We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Renalytix Plc | LSE:RENX | London | Ordinary Share | GB00BYWL4Y04 | ORD 0.25P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-1.50 | -4.29% | 33.50 | 32.00 | 35.00 | 35.00 | 33.50 | 35.00 | 92,711 | 16:26:48 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Services, Nec | 3.4M | -46.22M | -0.4626 | -0.72 | 33.48M |
Date | Subject | Author | Discuss |
---|---|---|---|
14/1/2021 08:16 | Bought some first thing too, bonkers price action | donald pond | |
14/1/2021 08:14 | If they execute to plan we could easily see a mkt cap of 10bn usd+ in 3-5 years. Still in the foothills here but the US at least seems to be waking up. | mr roper | |
14/1/2021 08:12 | Yep grabbed some more! | lottsgold | |
14/1/2021 08:11 | It should be music to investors ears, when the CEO can effectively and clearly state not only the 'initial' very large target market, but importantly why there are no direct competitors and effectively communicate and demonstrate the 'very high' barriers to entry. | wan | |
14/1/2021 04:39 | Renalytix finished up over 18% at $20.50 on Nasdaq. I make that equivalent to £8.25 per share. During the presentation Co-founder and CEO James McCullough also referred to Kantaro's antibody test as important testing technology and that they are making great strides to get this test out (EKF also gets mentioned in this regard). He states that quantitative antibody testing will be a significant issue in 2021 and 'beyond'. The following article adds more colour and some transparency regarding the FDA approval, which looks set to change, but EKF can already distribute in Europe on the basis of a fully quantitative test - Next-gen antibody tests promise more answers to Covid-19 questions The new tests can open a window into the duration of immunity and to the antibody levels needed to sustain it. But first, a universal standard is needed to ensure results are comparable between tests. By JOEL BERG 11th January 2021 “There’s still a lot to be learned,” said Michael Haydock, a senior director at Informa Pharma Intelligence in London. For example, he said, researchers don’t know if there is a threshold number of antibodies a person needs to maintain immunity, Haydock said. Quantitative tests could help pinpoint a threshold and track whether antibodies fall below it, potentially necessitating a booster vaccine. “Measuring that is going to be very important,” Haydock said in a phone interview. Tests also may be able to quantify differences in immune response based on age, race and other factors. In addition, quantitative tests can be used to assess people who have recovered from Covid-19 and want to donate plasma for use in convalescent plasma therapy, a treatment for the virus. Researchers also may be interested in understanding the response to Covid-19 vaccines among those who are already on therapies that modify their immune systems. “That’s the nature of this pandemic, that you’re trying to move forward when you have more questions than you have answers. Antibody testing can help answer those questions,” said Sara Barrington, chief commercial officer for Kantaro Biosciences. The New York-based company offers a quantitative antibody test for Covid-19 using technology developed at Mount Sinai Health System early in the pandemic. Kantaro is a joint venture between Mount Sinai and RenalytixAI, a diagnostics company based in the United Kingdom. Complicating the issue is the lack of an agreed-upon standard for measuring antibodies. However, clarity is on the horizon. The World Health Organization is expected to set standards soon, Barrington said in a phone interview. “With an international standard, you’d be able to compare the results across different tests,” said Erik Lium, Kantaro’s chairman and the chief commercial innovation officer at Mount Sinai. In November, the Food and Drug Administration approved Kantaro’s test for emergency use. But the approval comes with a qualification: the test, called COVID-SeroKlir, is considered semi-quantitative. The FDA appears to be waiting for the international standard to be set before declaring tests fully quantitative, Barrington said. However, European regulators are not waiting. They cleared COVID-SeroKlir for use as a fully quantitative test. Full story - | wan | |
13/1/2021 21:26 | The presentation was exceptional and the q and a very interesting. Good to see the US market leading the way. | mr roper | |
13/1/2021 21:23 | Huge volume in US, equivalent of 700,000 shares today compared to 87,000 in UK | donald pond | |
13/1/2021 21:06 | £7.50p equivalence to Nasdaq price. | busterdog2 | |
13/1/2021 19:52 | Only have a small stake here but looking like we've caught the eye of the NASDAQ bunch. Long may it continue! | lottsgold | |
13/1/2021 19:37 | THrough $22 now. +27% | mr roper | |
13/1/2021 19:26 | $rnlx absolutely flying on Nasdaq. Broke the 20 buck barrier and now up 18%. Hoping for similar here tomorrow. A break and run at 800p would be great. | mr roper | |
13/1/2021 16:54 | $rnlx at$19.50 I make that approx 720p | mr roper | |
13/1/2021 16:25 | Breaking out Stateside. When the CEO equates MCIT as being in at the start of the gold rush you can’t help but think a lot of folk have not cottoned on to the opportunity here. Absolutely huge. | mr roper | |
13/1/2021 15:55 | I concur, very encouraging indeed, and that's to say the least! | wan | |
13/1/2021 15:45 | Exceptional presentation. | mr roper | |
13/1/2021 07:55 | Good news thx | nw99 | |
13/1/2021 07:41 | Today's news demonstrates that the ground has been laid and the runway is clear subject to FDA approval. I have confidence for approval being attained this year due to Renalytix early engagement with FDA which has already resulted in KindneyIntelx being granted FDA breakthrough designation back in May 2019. I will be tuning into today's presentation. | wan | |
12/1/2021 22:20 | Good work from Stifel. Nicely timed for the day before the conference. Should get Renx some additional attention. | mr roper | |
12/1/2021 20:54 | Up 10% now, which is nice | mad foetus | |
12/1/2021 20:09 | From Seeking Alpha RNLX : Exact and Exact Sciences trade higher; Seen as beneficiaries from new CMS rule • 2:43 PM Finalization to the Medicare Coverage of Innovative Technology (“MCIT”) rule from CMS will benefit Renalytix (RNLX +3.9%), Exact Sciences (EXAS +3.7%), and Bio-Techne Corporation (TECH -0.6%), says Stifel in an industry update. Proposed in August, the new rule expects to cover devices with FDA breakthrough designation on the date of their respective market authorization leading to a four-year coverage thereafter. These devices have typically received Medicare coverage via National Coverage Decisions (“NCD”) or Local Coverage Decisions (“LCD”), a process that could take a year to finalize. While waiting for more details with the final ruling, the analysts attempt to identify the significant beneficiaries. With the breakthrough status, Renalytix’s KidneyIntelX platform is awaiting FDA approval. Exact's liver test and EPI test from Bio-Techne (NASDAQ:TECH) have breakthrough status and yet to file for FDA approval. | peterc1970 | |
11/1/2021 08:14 | My post from the Verici thread - Very important news today. This is an exciting development because invasive tissue biopsies remain the primary method of diagnosing fibrotic diseases. Thus, the ability to measure disease specific biomarkers non-invasively is highly desired. This potentially (at this stage) puts Verici firmly in Care DX's space (a large player) and potentially of great interest to the likes of Davita! It is a very large market that's unfortunately set to get much bigger, but importantly it's set get a lot more attention in terms of enabling transplants. | wan | |
06/1/2021 11:20 | Thanks for the heads-up Faz | wan | |
06/1/2021 10:52 | This announcement today shows just how much AZN - a RENX partner- is involved in treating chronic kidney disease. | faz | |
05/1/2021 15:54 | $rnlx just hit an ATH on the Nasdaq, hoping we follow suit here shortly... | mr roper |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions